Bristol-Myers Squibb: Hepatitis C, Chronic trials

The registry lists 37 Hepatitis C, Chronic studies with Bristol-Myers Squibb as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 1 8Phase 2 15Phase 3 7No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) InfectionTerminatedNCT03487848Phase 2Results posted
• Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)CompletedNCT02175966Phase 2Results posted
• A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1CompletedNCT02170727Phase 3Results posted
• Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIVTerminatedNCT01866930Phase 3Results posted
• Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C VirusCompletedNCT01628692Phase 2Results posted
• Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus InfectionCompletedNCT01492426Phase 3Results posted
• Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of CareCompletedNCT01359644Phase 2Results posted
• Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female SubjectsCompletedNCT00983957Phase 1Results posted
• A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected SubjectsCompletedNCT00663208Phase 2Results posted
• A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected SubjectsCompletedNCT00546715Phase 1/2Results posted
• Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC)TerminatedNCT03500562
• Study to Assess Clinical Outcomes in Chronic Hepatitis C Patients Previously Treated With Daclatasvir-Based RegimensCompletedNCT03366610
• Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in AdultsWithdrawnNCT03208322
• Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in AdultsCompletedNCT03181074
• A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)WithdrawnNCT02556086Phase 2
• Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization PeriodCompletedNCT02531269
• A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b InfectionCompletedNCT02496078Phase 3
• Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis CCompletedNCT02250001
• A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis CNo longer availableNCT02161939
• UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis CCompletedNCT02123654Phase 3
• EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis CNo longer availableNCT02097966
• UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic SubjectsCompletedNCT01979939Phase 3
• UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated CirrhosisCompletedNCT01973049Phase 3
• Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal DysfunctionCompletedNCT01708889Phase 1
• Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis CWithdrawnNCT01629732Phase 2
• Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical TrialCompletedNCT01525810
• Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected PatientsWithdrawnNCT01525212Phase 1
• Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical TrialCompletedNCT01492504
• Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available MedicationsCompletedNCT01455090Phase 2
• A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype IWithdrawnNCT01142700Phase 2
• Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of CareCompletedNCT01012895Phase 2
• Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus InfectionStatus unknownNCT01001754Phase 2
• Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C VirusCompletedNCT00971308Phase 1
• A Multiple Ascending Dose Study of BMS-650032 in HCV Infected SubjectsCompletedNCT00722358Phase 2
• A Single Ascending Dose Study of BMS-791325 in HCV Infected SubjectsCompletedNCT00664625Phase 1/2
• Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus InfectionCompletedNCT00565539Phase 1
• A Single Ascending Dose Study of BMS-650032 in HCV Infected SubjectsCompletedNCT00559247Phase 1/2